Compare RKDA & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RKDA | ACXP |
|---|---|---|
| Founded | 2002 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8M | 6.8M |
| IPO Year | 2015 | 2021 |
| Metric | RKDA | ACXP |
|---|---|---|
| Price | $3.68 | $3.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $143.67 |
| AVG Volume (30 Days) | 16.4K | ★ 51.9K |
| Earning Date | 11-07-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,173,000.00 | N/A |
| Revenue This Year | $21.31 | N/A |
| Revenue Next Year | $28.33 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.31 | N/A |
| 52 Week Low | $2.53 | $3.17 |
| 52 Week High | $10.31 | $25.00 |
| Indicator | RKDA | ACXP |
|---|---|---|
| Relative Strength Index (RSI) | 47.28 | 34.59 |
| Support Level | $3.48 | $3.17 |
| Resistance Level | $3.76 | $4.48 |
| Average True Range (ATR) | 0.18 | 0.36 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 43.09 | 15.54 |
Arcadia Biosciences Inc is a producer and marketer of plant-based food and beverage products. It is engaged in science-based approaches to developing high-value crop improvements in wheat, soy, and hemp, designed to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health, and wellness products, and their viability for industrial applications. The company's consumer brands in the food, beverage, and body care categories include GoodWheat high-fiber pasta, Zola coconut water, and others.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.